Objective To test short course, low dose liposomal amphotericin B as single or daily infusion treatment in Indian visceral leishmaniasis (kala-azar).
Introduction
Up to half of the world's cases of visceral leishmaniasis (kala-azar) occur in India, and about 90% of Indian patients live in the state of Bihar.
1 2 In the past five years, pentavalent antimony has become ineffective for treating visceral leishmaniasis in Bihar and other drugs have to be used. 3 4 Alternative effective treatments include oral miltefosine for 28 days (now completing phase III testing), 4 5 daily injections of aminosidine for 21 days, 6 infusions of conventional amphotericin B given daily for 20 days or on alternate days for 30 days, 4 7 and short courses of infusions of a lipid formulation of amphotericin B. 4 8-12 Although these treatments have a cure rate of over 90%, the drugs are still under evaluation and either have a prolonged or difficult to tolerate regimen or are prohibitively expensive. 4 Recently, we tested low dose liposomal amphotericin B in Indian patients in Bihar in whom antimony had failed. 13 A short course, five day treatment regimen consisting of 0.75 or 1.5 mg/kg/day (total doses 3.75 and 7.5 mg/kg) induced long term cure in 89% and 93% of patients, respectively. Increasing the dose to 3 mg/kg/day (total dose 15 mg/kg), which is in the range used in most previous trials, [10] [11] [12] gave a 97% cure rate. 13 We conducted a pilot study to determine whether our five day regimen could be abbreviated further. Patients were treated with a low total dose (5 mg/kg), which was divided and administered over five days or given as a single infusion.
Participants and methods

Entry and exclusion criteria
This open label study was carried out at the Kala-Azar Medical Research Centre in Muzaffarpur, Bihar, where visceral leishmaniasis caused by Leishmania donovani is endemic. It was approved by the ethics committee of the Institute of Medical Sciences, Banaras Hindu University, Varanasi.
Patients of any age with visceral leishmaniasis caused by L donovani were eligible if they had symptoms or signs of the disease (fever, weight loss, splenomegaly) and parasites were found by microscopy in a splenic aspirate smear. 9 Patients were excluded if they were pregnant or breast feeding, HIV positive, had a serious concurrent infection such as tuberculosis or bacterial pneumonia, or if they had a granulocyte count < 1×10 as once daily infusions of 1 mg/kg for five consecutive days. An independent statistician prepared the randomisation envelopes using a computer based random number generator. The study staff opened consecutively numbered envelopes containing the treatment assignment after eligible patients fulfilled the entry criteria.
Treatment was started within three days after splenic aspiration. The dose was given as a 60 minute intravenous infusion with no pretreatment with antipyretic drugs. 13 Patients were examined daily and remained in the unit until 14 days after the last infusion, at which time splenic aspiration and laboratory evaluation were repeated. We graded parasite density scores for aspirates taken before and after treatment in a blinded fashion using a conventional logarithmic scale of 0 (no parasites per 1000 oil immersion fields) to > 6 ( > 100 amastigotes per field). 9 Since we could not rationalise giving the single dose group subjects four additional placebo infusions, clinicians caring for the patients were not blinded to the treatment given.
We defined apparent cure 14 days after treatment ended as absence of fever, clinical improvement, reduction in spleen size, and a splenic aspirate score of 0 (apparent parasitological cure). 9 13 Definitive cure, assessed after six months of follow up, was defined as being healthy with no signs or symptoms of relapse. 9 13 
Statistical analysis
We compared response rates in the treatment groups by Fisher's exact test and calculated exact binomial 95% confidence intervals for the individual proportions responding to each treatment regimen. The objective of this study was to gather preliminary data on the relative efficacy of two treatments that would, if the results warranted it, inform the design of a more precise trial with appropriate statistical power.
Results
Patient characteristics and initial responses
The figure shows the flow of participants through the trial, and table 1 summarises the clinical features at entry to the study. Thirty six subjects had not responded to pentavalent antimony (sodium antimony gluconate, 20 mg/kg per day for >28 days 3 9 ); none had received amphotericin B. The groups were well matched except for haemoglobin concentration and platelet count (table 1) .
At entry, all 46 patients in the single dose group and 43 of 45 in the five dose group had fever. Seven days after treatment started, 45 of the single dose group and 43 of the five dose group had no fever, and mean duration of fever was identical in the two groups (2.6 (0.3) v 2.6 (0.4) days). At evaluation, 14 days after the last amphotericin infusion (table 2), none of the 91 participants had fever and all but one in each group had no parasites in splenic aspirate smears and fulfilled the criteria for apparent cure. One patient in each group had scanty parasites in the repeat aspirate smear and their treatment was designated as a failure. Compared with baseline, patients had reduced spleen size and increased white blood cell count, haemoglobin concentration, and platelet count (table 1).
Adverse reactions
Twenty four (52%) patients in the single dose group and 20 (44%) in the five dose group had no reaction during or after any infusion. In the remaining patients, reactions were mainly mild, related to the infusion (typical of reactions associated with amphotericin B), and seldom persisted beyond one or two hours after the end of the infusion. In the single dose group, three patients experienced increased temperature alone, one chills alone, and 18 both; two patients vomited once. In the five dose group, four patients had at least one episode of higher fever alone, one chills alone, and 18 both; two had brief vomiting and two had transient back pain. Blood urea nitrogen and creatinine concentrations did not change from day 0 in either group (table 1) .
Outcome and retreatment
We followed all apparently cured patients for six months after treatment. 3 9 13 Five patients had asymptomatic relapses that were confirmed by microscopy (three in single dose group, two in five dose group, table 2). All other participants were asymptomatic, appeared healthy, and were judged to have a definitive cure. Thus, overall, liposomal amphotericin (5 mg/kg) cured 92% of patients (84/91), 91% (95% confidence interval 79% to 98%) of those treated with a single infusion and 93% (82% to 99%) of those who received five daily infusions of 1 mg/kg (table 2) .
The five patients who relapsed and the two initial non-responders were retreated with amphotericin B deoxycholate (15 alternate day infusions of 1 mg/kg). All responded and were considered cured six months later.
Discussion
In this uncontrolled, observational pilot study, we found that low dose liposomal amphotericin induced rapid resolution of fever, prompt clinical improvement, and an overall cure rate of 92%. We found no evidence that delivering the total dose of 5 mg/kg as a single infusion was less effective than splitting the dose over five days. However, the small sample size means that the study did not have enough power to prove the equivalence of these two regimens.
A second limitation of the study is that clinical assessment of the initial and six month responses to treatment was not blinded. Nevertheless, the definition of initial cure required the splenic aspirate smear to be free of parasites on microscopy, and this test was done blinded. In addition, the clinical presentation of relapse is not usually affected by previous treatment, and relapse was objectively confirmed in a splenic aspirate.
Resistance
Another issue is whether patients who relapse or do not respond to low dose treatment could develop resistance to amphotericin B. Our approach is to retreat patients in whom treatment fails with conventional amphotericin B. 4 13 Although the results are limited, none of the 13 patients who failed to respond to low dose liposomal amphotericin B 13 or the 32 who did not respond to short course, low dose amphotericin B lipid complex treatment 4 have shown clinical resistance to amphotericin B.
Cost of treatment
The principal rationale for testing low or single dose regimens is to identify a treatment that is not only effective and convenient but affordable. Commercially available lipid formulations of amphotericin B are expensive, and the cost of even short course or low dose regimens 4 10 14 are an insurmountable obstacle in the developing world.
1 For example, US average wholesale prices for the various lipid formulations of amphotericin B are $188 (£125) per 50 mg vial for AmBisome (liposomal), $93 per 50 mg for Amphotec (cholesterol dispersion), and $194 per 100 mg for Abelcet (lipid complex). 15 The regimen for liposomal amphotericin B approved by the US Federal Drugs Administration for visceral leishmaniasis consists of 3 mg/kg given on days 1-5, 14, and 21 (total dose, 21 mg/kg). 16 AmBisome currently costs about $173 per 50 mg in India, and in a 25 kg patient the regimen equates to about $1900. The regimen used in our study, which produced cure rates of 92% rather than 97%, would cost $519. This is more affordable but still too high.
Amphotericin B deoxycholate (Fungizone) is cheaper than the lipid formulations (US wholesale price $17 per 50 mg vial, retail price in India $6 per 50 mg vial). 4 14 It is now first line treatment for visceral leishmaniasis in Bihar because of antimony resistance and produces cure rates of > 95% in patients who complete treatment. However, the regimens are prolonged and therefore expensive, require daily infusions for 20 days or (more usually) on alternate days over 30 days, and are not always well tolerated. 4 17 Short course regimens using drugs such as AmBisome or Abelcet, 9 13 which also seem to produce fewer adverse reactions than the deoxycholate form, 4 13 are therefore attractive.
Although hospital stay and costs can be appreciably reduced by short courses and especially single dose regimens, 4 14 these savings do not offset the cost of the drug in countries such as India, where hospital charges are low. If definitive trials establish the efficacy of our low dose regimen, drug companies will have to cut prices for the potential benefits to be realised.
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Commentary: cost and resistance remain issues
Diana N J Lockwood
Leishmania are inoculated into humans by the bite of infected sandflies. In the Indian subcontinent the infection is anthroponotic; man is the only known reservoir. The close proximity of humans, cows, and sandflies in Indian villages provides ideal conditions for spread of the disease. Control of the disease depends on controlling sandflies and detecting and treating human disease early. Since the end of the antimalarial campaigns there has been little systematic use of insecticides, and the proposal to ban the use of the cheap and effective dicophane (DDT) poses an extra threat to control measures. Treatment is therefore the mainstay of control. Pentavalent antimonials have been the treatment of choice since the 1920s, but resistance is increasing in India. Thus there is an urgent need for new drugs. Currently three drugs are being evaluated for visceral leishmaniasis in India, liposomal amphotericin B, paromomycin, and oral miltefosine. The exclusion criteria used in the study by Sundar et al show the degree of weight loss and the effects of disease and splenomegaly on the haemoglobin, granulocyte, and platelet counts. Splenic aspirate remains the best method of diagnosis. It is simpler and less painful than a bone marrow aspirate and is the only means of assessing the parasitic response to treatment.
This study shows that a one day course of treatment can cure the disease in 90% of very sick patients. This is good but tantalising news for patients, many of whom are landless peasants. Their earning capacities will have been seriously impaired by their disease. The families' financial losses are increased because relatives have to care for and feed patients while they are in hospital.
Nevertheless, we cannot be sure that a 90% cure rate would be adequate to prevent the emergence of resistance. Studying drug resistance in leishmaniasis is difficult. Amastigote-macrophage cultures have to be used because there are no molecular markers of resistance. But monitoring drug resistance is important, especially when monotherapy is used in an anthroponotic focus. Perhaps short combined regimens should be developed to ensure that the range of drugs for leishmaniasis remains adequate.
The drug treatment of leishmaniasis highlights the problems of delivering effective drugs to resource poor settings. Paromomycin has been shown to be more effective than antimony, 2 but the drug has still not yet reached patients. Four years ago, the drug had no manufacturer. An industrial partner has now been found, but the tropical disease research programme at the World Health Organization does not have the funds to complete the comparative studies needed for drug registration.
Liposomal amphotericin remains an extremely expensive drug that no patient or health service in the developing world is ever going to be able to buy, and there are no patient activists to pressurise the manufacturer into providing the drug at an affordable price.
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